Vatreptacog Alfa (Activated)
Inherited Blood Coagulation Disorder
Explore 3 assets in Inherited Blood Coagulation Disorder →Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Novo Nordisk A/S
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01392547CT.gov Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors | — | Completed | — | — | — |
NCT00486278CT.gov Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Inherited Blood Coagulation Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vatreptacog Alfa (Activated) (this asset) | Novo Nordisk A/S | P3 | BB · 69 |
| Turoctocog Alfa | Novo Nordisk A/S | P4 | A |
| Eptacog Alfa (Activated) | Novo Nordisk A/S | P4 | A |
| Nonacog Beta Pegol | Novo Nordisk A/S | P3 | A |
| N8-GP | Novo Nordisk A/S | P3 | A |
| Human Antihemophilic Factor/Von Willebrand Factor Complex | Assiut University | P4 | BB |
| Feiba | Novo Nordisk A/S | P4 | BB |
| Factor Ix | Novo Nordisk A/S | P4 | BB |
| Concizumab | Novo Nordisk A/S | P2 | BB |
+9 more in the Inherited Blood Coagulation Disorder cohort
Other indications for Vatreptacog Alfa (Activated)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hemophilia B | — | P3 | BB · 69 |
| Hemophilia A | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vatreptacog Alfa (Activated) in Inherited Blood Coagulation Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vatreptacog-alfa-activated-inherited-blood-coagulation-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →